PRIMARY STUDY
β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis
Key Findings: The study represents significant implications for clinical research and strongly supports the effectiveness of β-Caryophyllene as a novel molecule to target in the development of effective therapeutic agents for MS.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Brazil
Year of Pub: 2017
Cannabinoids Studied: AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids
Phytocannabinoid Source: Not Applicable
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB2
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Dosing Regimen: BCP (25 or 50 mg/kg)
Clinical Relevance: BCP preventively or therapeutically blocked the development and progression of clinical and neurological signs of EAE, which was correlated with the hindrance of immune cell activation, neuroinflammation, and demyelinating processes in the CNS.
Link to study
